Acasti Pharma Inc (ACST) Stock Price, Chart & News

Up to 60% off Profit Pro - Limited Time Offer!

Winter Sale

Up to 60% off Profit Pro - Limited Time Offer!

60% off Profit Pro - Limited Time Offer!

ACST

3.37

USD-0.03-0.88%

Overview

Profile

Statistics

Earnings

Financials

Holders

Trends

Insider Trades

Filings

News

Chart

Latest News

@eWhispers

2 years

Tuesday morning #earnings https://t.co/lObOE0dgsr $LEN $RSVR $ACST https://t.co/3GjKvj7MvV

@eWhispers

2 years

Monday morning #earnings https://t.co/lObOE0dgsr $ALX $STNG $WEBR $KELYA $THS $OLK $AGTC $GTX $ROIV $ACST https://t.co/clDYSK85nL

Analysts Recommendations

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Day Range

0USD

3.37USD

52 Week Range

1.98USD

3.60USD

Market Cap

34.17MUSD

Billionaire Owners

Get Full Access with Profit PRO

See which Billionaires own this investment

About

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

General Information

Type

Common Stock

Exchange

NASDAQ

Currency Code

USD

Currency Name

US Dollar

Country Name

USA

Country ISO

ISIN

CA00430K8730

CUSIP

00430K105

Sector

Healthcare

Industry

Biotechnology

Fiscal Year End

March

IPO date

Updated At

Highlights

PE Ratio

PEG Ratio

Book Value

5.86

Dividend Share

Dividend Yield

Earnings Share

-1.43

Wall Street Target Price

7.97

EPS Estimate Current Year

-1.44

EPS Estimate Next Year

-1.12

EPS Estimate Current Quarter

-0.25

EPS Estimate Next Quarter

-0.31

Most Recent Quarter

Profitability

Revenue TTM

115,000

Gross Profit TTM

120,000

EBITDA

-13,266,000

Profit Margin

0.00%

Return On Assets TTM

-11.62%

Return On Equity TTM

-18.56%

Revenue Per Share TTM

0.005

Qtly Revenue Growth YOY

0.00%

Diluted Eps TTM

-1.43

Qtly Earnings Growth YOY

0.00%

Valuation

Trailing PE

0.00

Forward PE

Price Sales TTM

208.3872

Price Book MRQ

0.5295

Enterprise Value Revenue

Enterprise Value EBITDA

Peers analysis

BGNEBeiGene Ltd
185.00
1.86%
CSLLYCSL Ltd
88.70
1.04%
VRTXVertex Pharmaceuticals Inc
410.66
0.67%
ARGXargenx NV ADR
632.04
0.33%
REGNRegeneron Pharmaceuticals Inc
716.68
0.31%

CMXHFCSL Limited
173.50
0.00%
UCBJFUCB SA
198.28
0.00%
UCBJYUCB SA ADR
99.02
-0.96%
ALNYAlnylam Pharmaceuticals Inc
242.00
-0.60%
BNTXBioNTech SE
113.80
-0.10%

What are you waiting for?Start making profit today

Tools

Plans

Markets

Resources

Compare

Profit mobile app

Discover the world of finance in your pocket

2024